Administering the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access; Public Meeting; Request for Comments, 28493-28496 [2017-12641]
Download as PDF
Federal Register / Vol. 82, No. 119 / Thursday, June 22, 2017 / Notices
other stakeholder feedback and
notification of potential violations of the
FD&C Act, as amended by the Tobacco
Control Act.
FDA created a Tobacco Call Center
(with a toll-free number: 1–877–CTP–
1373). Callers are able to report
potential violations of the Tobacco
Control Act, and FDA may conduct
followup investigations based on
information received. When callers
report a violation, the caller will be
asked to provide as much certain
information as they can recall,
including: The date the potential
violation occurred; product type (e.g.,
cigarette, smokeless, roll-your-own,
cigar, e-cigarette, hookah, pipe tobacco);
tobacco brand; potential violation type;
type of potentially violative promotional
materials; who potentially violated; and
the name, address, phone number, and
email address of the potential violator.
The caller will also be asked to list the
potential violator’s Web site (if
available), describe the potential
violation, and provide any additional
files or information pertinent to the
potential violation.
FDA currently provides a form that
may be used to solicit this information
from the caller (Form FDA 3779,
Potential Tobacco Product Violations
Report), and seeks renewal of Form FDA
3779. This form is posted on FDA’s Web
site. The public and interested
stakeholders are also able to report
information regarding possible
28493
violations of the Tobacco Control Act
through the following methods: Calling
the Tobacco Call Center using the
Center for Tobacco Products’ (CTP) tollfree number; using a fillable Form FDA
3779 found on FDA’s Web site;
downloading a PDF version of the form
to send via email or mail to FDA;
requesting a copy of Form FDA 3779 by
contacting CTP and sending by mail to
FDA; and sending a letter to FDA’s CTP.
In the Federal Register of November
7, 2016 (81 FR 78166), FDA published
a 60-day notice requesting public
comment on the proposed collection of
information. No comments were
received.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Activity and FDA Form 3779
Number of
respondents
Number of
responses per
respondent
Total annual
responses
Average burden
per response
Total hours
Reporting violations of the FD&C Act, as
amended by the Tobacco Control Act via telephone, Internet form, mail, smartphone application, or email.
750
2
1,500
0.25 (15 minutes) ...........
375
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
sradovich on DSK3GMQ082PROD with NOTICES
FDA estimates that submitting the
information (by telephone, Internet
form, paper form by mail, or email) will
take 0.25 hour (i.e., 15 minutes) per
response. Based on the type and rate of
reporting that has been submitted
through the Potential Tobacco Violation
Reporting Form in the past, in addition
to the increase that FDA has recently
experienced in the rate of reporting due
to the recent rule, ‘‘Deeming Tobacco
Products To Be Subject to the Federal
Food, Drug, and Cosmetic Act, as
Amended by the Family Smoking
Prevention and Tobacco Control Act,’’
FDA estimates the number of annual
respondents to this collection of
information will be 750, who will each
submit 2 reports by telephone, Internet
form, paper form, or email. Each report
is expected to take 0.25 hour to
complete and submit; therefore, total
burden hours for this collection of
information is estimated to be 375 hours
(1,500 responses x 0.25 hour per
response).
Dated: June 12, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning,
Legislation, and Analysis.
[FR Doc. 2017–13018 Filed 6–21–17; 8:45 am]
BILLING CODE 4164–01–P
VerDate Sep<11>2014
16:08 Jun 21, 2017
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2017–N–3615]
Administering the Hatch-Waxman
Amendments: Ensuring a Balance
Between Innovation and Access;
Public Meeting; Request for Comments
AGENCY:
Food and Drug Administration,
HHS.
Notice of public meeting;
request for comments.
ACTION:
The Food and Drug
Administration (FDA or the Agency) is
announcing the following meeting: ‘‘The
Hatch-Waxman Amendments: Ensuring
a Balance Between Innovation and
Access.’’ This public meeting is
intended to provide the public an
opportunity to submit comments
concerning administration of the HatchWaxman Amendments to the Federal
Food, Drug, and Cosmetic Act (FD&C
Act) to help ensure the intended balance
between encouraging innovation in drug
development and accelerating the
availability to the public of lower cost
alternatives to innovator drugs is
maintained.
SUMMARY:
The meeting will be held on July
18, 2017, from 9 a.m. to 5 p.m. The
deadline for submitting comments
DATES:
Jkt 241001
PO 00000
Frm 00026
Fmt 4703
Sfmt 4703
regarding this meeting is September 18,
2017.
ADDRESSES: The meeting will be held at
the FDA White Oak Campus, 10903
New Hampshire Ave., Bldg. 31
Conference Center, the Great Room (Rm.
1503), Silver Spring, MD 20993.
Entrance for the public meeting
participants (non-FDA employees) is
through Building 1, where routine
security check procedures will be
performed. For parking and security
information, please refer to https://
www.fda.gov/AboutFDA/
WorkingatFDA/BuildingsandFacilities/
WhiteOakCampusInformation/
ucm241740.htm.
You may submit comments as
follows. Please note that late, untimely
filed comments will not be considered.
Electronic comments must be submitted
on or before September 18, 2017. The
https://www.regulations.gov electronic
filing system will accept comments
until midnight Eastern Time at the end
of September 18, 2017. Comments
received by mail/hand delivery/courier
(for written/paper submissions) will be
considered timely if they are
postmarked or the delivery service
acceptance receipt is on or before that
date.
Electronic Submissions
Submit electronic comments in the
following way:
E:\FR\FM\22JNN1.SGM
22JNN1
28494
Federal Register / Vol. 82, No. 119 / Thursday, June 22, 2017 / Notices
sradovich on DSK3GMQ082PROD with NOTICES
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2017–N–3615 for ‘‘Administering the
Hatch-Waxman Amendments: Ensuring
a Balance Between Innovation and
Access; Public Meeting; Request for
Comments.’’ Received comments, those
filed in a timely manner (see
ADDRESSES), will be placed in the docket
and, except for those submitted as
‘‘Confidential Submissions,’’ publicly
viewable at https://www.regulations.gov
or at the Dockets Management Staff
between 9 a.m. and 4 p.m., Monday
through Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
VerDate Sep<11>2014
16:08 Jun 21, 2017
Jkt 241001
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://www.gpo.gov/
fdsys/pkg/FR-2015-09-18/pdf/201523389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT:
Philip Bonforte, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 75, Rm. 1668,
Silver Spring, MD 20993, 240–402–
6980, email:
GenericDrugPolicy@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
With the Drug Price Competition and
Patent Term Restoration Act of 1984
(Pub. L. 98–417) (Hatch-Waxman
Amendments), Congress intended to
strike a balance between encouraging
innovation in drug development and
accelerating the availability to the
public of lower cost alternatives to
innovator drugs. See H.R. Rep. No. 98–
857 (Part I), 98th Cong, 2d Sess. At 14–
15 (1984), reprinted in 1984
U.S.C.C.A.N. 2647–48; see also, e.g.,
Teva Pharmaceutical Industries Ltd. v.
Crawford, 410 F.3d 51, 54 (D.C. Cir.
2005). To provide incentives intended
to encourage the development of
innovative new drugs and new uses of
approved drugs, the Hatch-Waxman
Amendments provided sponsors of
innovator drugs with exclusivity and
PO 00000
Frm 00027
Fmt 4703
Sfmt 4703
protections based on patent listings that
protect certain aspects of innovator
drugs from generic competition for
certain periods of time. To ensure the
availability of generic drugs, the HatchWaxman Amendments created an
abbreviated new drug application
(ANDA) process that allows sponsors of
generic drugs to rely on the Agency’s
finding of safety and effectiveness for
innovator drugs in seeking approval of
their generic products after patent or
marketing exclusivity protections held
by the innovator expire or are otherwise
removed.
FDA’s generic drug program has
dramatically expanded access to quality,
affordable generic medicines. According
to the IMS Institute for Healthcare
Informatics, generic drugs saved the U.S
healthcare system $1.68 trillion from
2005–2014.1
Over the past several years, the
Agency has undertaken major initiatives
to expand access to quality, affordable
generic medicines. For example,
pursuant to the Generic Drug User Fee
Amendments of 2012 (GDUFA I), FDA
modernized the ANDA review program,
and adopted metric goals to promote
timely and predictable ANDA review.
As a result, in Fiscal Year 2016,
combined ANDA approvals and
tentative approvals reached record
highs. Pursuant to the proposed GDUFA
II,2 FDA would further enhance the
ANDA review program by clarifying
regulatory expectations early in product
development, helping applicants
develop more complete submissions,
and giving applicants more
opportunities to address deficiencies
within a review cycle, all with the goal
of reducing the number of review cycles
necessary to obtain ANDA approval.
The development and approval of an
innovator drug, and the subsequent
approval and marketing of a generic
version, together make up the life cycle
of that drug product as contemplated by
the Hatch-Waxman Amendments.
At the front end of the life cycle,
innovation in drug products—including
improvements to approved innovator
drug products—provides life-changing
and oftentimes life-saving therapeutic
benefits to patients. In enacting the
Hatch-Waxman Amendments, Congress
recognized the importance of providing
incentives to develop new products, and
1 IMS Health Institute for Healthcare Informatics
(April 2015), available at https://
www.imshealth.com/en/thought-leadership/
quintilesims-institute/reports.
2 GDUFA Reauthorization Performance Goals and
Program Enhancements Fiscal Years 2018–2022
(October 2016), available at https://www.fda.gov/
downloads/forindustry/userfees/
genericdruguserfees/ucm525234.pdf.
E:\FR\FM\22JNN1.SGM
22JNN1
sradovich on DSK3GMQ082PROD with NOTICES
Federal Register / Vol. 82, No. 119 / Thursday, June 22, 2017 / Notices
new conditions of use for approved
products. To further incentivize
innovation, Congress subsequently
established additional incentives in the
form of exclusivity periods for drug
products studied in pediatric
populations, rare diseases, and new
antibiotic treatments. Congress also
provided a period of 180-day exclusivity
for certain first generic applications as
an incentive for generic manufacturers
to challenge patents on innovator drugs
that might otherwise prevent approval
or delay generic entry into the market.
These exclusivities, which are generally
designed to reward sponsors with finite
periods of limited or no generic or
follow-on competition, were intended to
expand the availability of safe and
effective medicines for which
insufficient or no treatment previously
existed or to encourage generic drug
development that might not have been
profitable otherwise.
In some cases, however, the legal
framework surrounding these
exclusivities may have been applied to
delay generic competition to an extent
that may not have been intended by the
Hatch-Waxman Amendments, and in
ways that may not serve the public
health. Relatedly, certain elements of
the approval process for both innovator
and generic drugs have been used in
ways that may (depending on the
circumstances) inappropriately hinder
generic competition. For example,
innovators in some cases have made late
changes in patent use codes that create
new obstacles to previously acceptable
labeling carve-outs. The entry of generic
products to the marketplace is also
affected by factors external to regulation
under the FD&C Act—e.g., the outcome
of private party patent litigation, and
commercial decisions not to market
approved innovator or generic products.
In other cases, restrictions on the
distribution of innovator drug products,
whether voluntarily adopted by the
innovator or imposed as a requirement
of FDA regulation, have prevented
developers from accessing the product
samples needed for testing to support
ANDAs or other follow-on applications.
FDA will hold a public meeting on
July 18, 2017, 9 a.m. to 5 p.m., to
provide an opportunity for all interested
stakeholders to submit comments
concerning the appropriate balance
between encouraging innovation in drug
development and accelerating the
availability to the public of lower cost
alternatives to innovator drugs.
The format of the meeting involves
presentations from the public only. The
Agency will not be inviting specific
presenters; rather, with this document,
FDA is soliciting presentations from
VerDate Sep<11>2014
16:08 Jun 21, 2017
Jkt 241001
interested stakeholders. FDA also
invites interested persons to submit
written comments to the docket on the
topics described in section II.
II. Topics for This Public Meeting
FDA is soliciting input from the
public concerning how best to preserve
the balance Congress intended to strike
in the Hatch-Waxman Amendments
between encouraging innovation in drug
development and accelerating the
availability to the public of lower cost
alternatives to innovator drugs.
Preserving this balance is critical to the
public health, and innovators, generic
drug manufacturers, and FDA (among
others) all have a role to play in
maintaining it. This public meeting is
part of an effort to create a broader
understanding of the interplay between
the existing legal and regulatory
framework, available incentives and
marketplace practices, and consumer
access to generic drugs.
The Agency welcomes any relevant
information that stakeholders wish to
share. We are particularly interested in
stakeholder input on the following
questions:
1. How has the balance struck in the
Hatch-Waxman Amendments been
affected by practices and trends related
to the following:
a. Exclusivity periods,
b. Patents (including patent listing
procedures),
c. Innovator drug product labeling,
d. Post-approval changes to innovator
drug products, e.g., reformulations, and
e. Other regulatory processes,
including the citizen petition process?
2. The drugs described in more than
half of all FDA-approved ANDAs are
never marketed, marketed only after a
substantial delay after approval, or
marketed only intermittently. Such
failures to market contribute to drug
shortages, and hinder consumer access
to approved products. What
marketplace dynamics dis-incentivize
the marketing of approved generic
products? What should FDA do, within
its statutory authority, to help more
approved generics reach consumers?
3. For approximately 10 percent of all
innovator drugs, patent and exclusivity
protections have expired, but FDA has
not received an ANDA. Are there market
niches where the Hatch-Waxman
Amendments incentives to develop an
ANDA are insufficient? Similarly, are
there niches where the incentives are
insufficient to seek new drug approval
of a marketed unapproved drug product
that in turn could serve as a Reference
Listed Drug? What should FDA do,
consistent with its legal authority, to
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
28495
encourage submission development in
any such market niches?
4. The statutory requirement that Risk
Evaluation and Mitigation Strategies
(REMS) that include elements to assure
safe use (ETASU) be implemented
through a ‘‘single shared system’’ relies
on brand and generic companies
agreeing on such a system before generic
drugs may come to market. In some
cases, challenges in reaching such an
agreement between the parties may
cause delays to generic competition.
How should FDA apply its statutory
authority to waive this requirement to
implement a ‘‘single shared system,’’ or
develop other administrative tools, to
avoid these delays?
5. Restrictions on distribution, either
required by innovators or as part of a
REMS ETASU, can prevent generic
companies from obtaining drug
products for bioequivalence and other
testing to support ANDA submissions.
FDA published a draft guidance for
industry, entitled ‘‘How to Obtain a
Letter from the Food and Drug
Administration Stating That
Bioequivalence Study Protocols Contain
Safety Protections Comparable to
Applicable Risk and Evaluation
Mitigation Studies for Reference Listed
Drugs,’’ in December 2014. Despite this
draft guidance, generic companies have
reported continuing difficulties
obtaining sufficient samples of drug
products for testing. What additional
actions should FDA take, within its
legal authority, to promote access to
these drug products for generic
companies seeking to conduct studies
required to support ANDA submissions?
6. What other elements of drug
product development, regulation, and
marketing have the potential to disrupt
the Hatch-Waxman Amendments’
balance between innovation and generic
availability, and how should the Agency
and other stakeholders address them?
Registration and Requests for Oral
Presentations: Send registration
information (including name, title, firm
name, address, telephone, email
address, and fax number), and written
material and requests to make oral
presentations, to the contact person by
July 3, 2017.
If you need special accommodations
due to a disability, please contact Philip
Bonforte (see FOR FURTHER INFORMATION
CONTACT) at least 7 days in advance.
Transcripts: Please be advised that as
soon as a transcript is available, it will
be accessible at https://
www.regulations.gov. It may be viewed
at the Dockets Management Staff (see
ADDRESSES).
E:\FR\FM\22JNN1.SGM
22JNN1
28496
Federal Register / Vol. 82, No. 119 / Thursday, June 22, 2017 / Notices
Dated: June 14, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning,
Legislation, and Analysis.
[FR Doc. 2017–12641 Filed 6–21–17; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Agency Information Collection
Activities: Submission to OMB for
Review and Approval; Information
Collection Request Title: Rural Health
Network Development Planning
Performance Improvement and
Measurement System Database, OMB
No. 0915–0384—Extension
Health Resources and Services
Administration (HRSA), Department of
Health and Human Services.
ACTION: Notice.
AGENCY:
In compliance with the
Paperwork Reduction Act of 1995,
HRSA has submitted an Information
Collection Request (ICR) to the Office of
Management and Budget (OMB) for
review and approval. Comments
submitted during the first public review
of this ICR will be provided to OMB.
OMB will accept further comments from
the public during the review and
approval period.
DATES: Comments on this ICR should be
received no later than July 24, 2017.
ADDRESSES: Submit your comments,
including the ICR Title, to the desk
SUMMARY:
officer for HRSA, either by email to
OIRA_submission@omb.eop.gov or by
fax to 202–395–5806.
FOR FURTHER INFORMATION CONTACT: To
request a copy of the clearance requests
submitted to OMB for review, email the
HRSA Information Collection Clearance
Officer at paperwork@hrsa.gov or call
(301) 443–1984.
SUPPLEMENTARY INFORMATION: When
submitting comments or requesting
information, please include the
information request collection title for
reference, in compliance with Section
3506(c)(2)(A) of the Paperwork
Reduction Act of 1995.
Information Collection Request Title:
Rural Health Network Development
Planning Performance Improvement and
Measurement System Database, OMB
No. 0915–0384—Extension.
Abstract: The purpose of the Rural
Health Network Development Planning
(Network Planning) program is to assist
in the development of an integrated
health care network, specifically for
entities that do not have a history of
formal collaborative efforts. Health care
networks can be an effective approach
to help smaller rural health care
providers and health care service
organizations align resources, achieve
economies of scale and efficiency, and
address challenges more effectively as a
group than as single providers. The
Network Planning program promotes
the planning and development of
healthcare networks to: (1) Achieve
efficiencies; (2) expand access to,
coordinate, and improve the quality of
essential health care services; and (3)
Number of
respondents
Form name
Number of
responses per
respondent
strengthen the rural health care system
as a whole.
Need and Proposed Use of the
Information: Performance measures for
the Network Planning program serve the
purpose of quantifying awardee-level
data that conveys the successes and
challenges associated with the grant
award. These measures and aggregate
data substantiate and inform the
objectives of the program. The approved
measures encompass the following
principal topic areas: network
infrastructure, network collaboration,
sustainability, and network assessment.
Likely Respondents: The respondents
for these measures are Network
Planning award recipients.
Burden Statement: Burden in this
context means the time expended by
persons to generate, maintain, retain,
disclose, or provide the information
requested. This includes the time
needed to review instructions; to
develop, acquire, install, and utilize
technology and systems for the purpose
of collecting, validating and verifying
information, processing and
maintaining information, and disclosing
and providing information; to train
personnel and to be able to respond to
a collection of information; to search
data sources; to complete and review
the collection of information; and to
transmit or otherwise disclose the
information. The total annual burden
hours, which are unchanged from the
currently approved form, are
summarized in the table below.
Total Estimated Annualized Burden
Hours:
Total
responses
Average
burden per
response
(in hours)
Total
burden hours
Rural Health Network Development Planning Program
Performance Improvement Measurement System ..........
21
1
21
1
21
Total ..............................................................................
21
........................
21
........................
21
Jason E. Bennett,
Director, Division of the Executive Secretariat.
[FR Doc. 2017–13019 Filed 6–21–17; 8:45 am]
sradovich on DSK3GMQ082PROD with NOTICES
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Committee on Vital and Health
Statistics: Meeting
Pursuant to the Federal Advisory
Committee Act, the Department of
Health and Human Services (HHS)
VerDate Sep<11>2014
16:08 Jun 21, 2017
Jkt 241001
announces the following special
workgroup activity.
Name: National Committee on Vital
and Health Statistics (NCVHS),
Subcommittee on Standards Meeting.
Date and Time: Monday, August 21,
2017: 9:00 a.m.–4:00 p.m.
Place: U.S. Department of Health and
Human Services, Hubert H. Humphrey
Building, 200 Independence Avenue
SW., Room 800, Washington, DC 20201,
(202) 690–7100.
Status: Open.
Purpose: The National Committee on
Vital and Health Statistics (NCVHS) is
PO 00000
Frm 00029
Fmt 4703
Sfmt 4703
the advisory body to the U.S.
Department of Health and Human
Services (HHS) Secretary on health data,
statistics, privacy, and national health
information policy. NCVHS’ role
includes advising HHS in the
implementation of the Administrative
Simplification provisions of the Health
Insurance Portability and
Accountability Act of 1996 (HIPAA) and
the Patient Protection and Affordable
Care Act of 2010 (ACA). The Standards
Subcommittee of NCVHS makes
recommendations to the full Committee
on health data standards, including
E:\FR\FM\22JNN1.SGM
22JNN1
Agencies
[Federal Register Volume 82, Number 119 (Thursday, June 22, 2017)]
[Notices]
[Pages 28493-28496]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-12641]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2017-N-3615]
Administering the Hatch-Waxman Amendments: Ensuring a Balance
Between Innovation and Access; Public Meeting; Request for Comments
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of public meeting; request for comments.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or the Agency) is
announcing the following meeting: ``The Hatch-Waxman Amendments:
Ensuring a Balance Between Innovation and Access.'' This public meeting
is intended to provide the public an opportunity to submit comments
concerning administration of the Hatch-Waxman Amendments to the Federal
Food, Drug, and Cosmetic Act (FD&C Act) to help ensure the intended
balance between encouraging innovation in drug development and
accelerating the availability to the public of lower cost alternatives
to innovator drugs is maintained.
DATES: The meeting will be held on July 18, 2017, from 9 a.m. to 5 p.m.
The deadline for submitting comments regarding this meeting is
September 18, 2017.
ADDRESSES: The meeting will be held at the FDA White Oak Campus, 10903
New Hampshire Ave., Bldg. 31 Conference Center, the Great Room (Rm.
1503), Silver Spring, MD 20993. Entrance for the public meeting
participants (non-FDA employees) is through Building 1, where routine
security check procedures will be performed. For parking and security
information, please refer to https://www.fda.gov/AboutFDA/WorkingatFDA/BuildingsandFacilities/WhiteOakCampusInformation/ucm241740.htm.
You may submit comments as follows. Please note that late, untimely
filed comments will not be considered. Electronic comments must be
submitted on or before September 18, 2017. The https://www.regulations.gov electronic filing system will accept comments until
midnight Eastern Time at the end of September 18, 2017. Comments
received by mail/hand delivery/courier (for written/paper submissions)
will be considered timely if they are postmarked or the delivery
service acceptance receipt is on or before that date.
Electronic Submissions
Submit electronic comments in the following way:
[[Page 28494]]
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
Mail/Hand delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2017-N-3615 for ``Administering the Hatch-Waxman Amendments:
Ensuring a Balance Between Innovation and Access; Public Meeting;
Request for Comments.'' Received comments, those filed in a timely
manner (see ADDRESSES), will be placed in the docket and, except for
those submitted as ``Confidential Submissions,'' publicly viewable at
https://www.regulations.gov or at the Dockets Management Staff between
9 a.m. and 4 p.m., Monday through Friday.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Philip Bonforte, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 75, Rm. 1668, Silver Spring, MD 20993, 240-402-
6980, email: GenericDrugPolicy@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
With the Drug Price Competition and Patent Term Restoration Act of
1984 (Pub. L. 98-417) (Hatch-Waxman Amendments), Congress intended to
strike a balance between encouraging innovation in drug development and
accelerating the availability to the public of lower cost alternatives
to innovator drugs. See H.R. Rep. No. 98-857 (Part I), 98th Cong, 2d
Sess. At 14-15 (1984), reprinted in 1984 U.S.C.C.A.N. 2647-48; see
also, e.g., Teva Pharmaceutical Industries Ltd. v. Crawford, 410 F.3d
51, 54 (D.C. Cir. 2005). To provide incentives intended to encourage
the development of innovative new drugs and new uses of approved drugs,
the Hatch-Waxman Amendments provided sponsors of innovator drugs with
exclusivity and protections based on patent listings that protect
certain aspects of innovator drugs from generic competition for certain
periods of time. To ensure the availability of generic drugs, the
Hatch-Waxman Amendments created an abbreviated new drug application
(ANDA) process that allows sponsors of generic drugs to rely on the
Agency's finding of safety and effectiveness for innovator drugs in
seeking approval of their generic products after patent or marketing
exclusivity protections held by the innovator expire or are otherwise
removed.
FDA's generic drug program has dramatically expanded access to
quality, affordable generic medicines. According to the IMS Institute
for Healthcare Informatics, generic drugs saved the U.S healthcare
system $1.68 trillion from 2005-2014.\1\
---------------------------------------------------------------------------
\1\ IMS Health Institute for Healthcare Informatics (April
2015), available at https://www.imshealth.com/en/thought-leadership/quintilesims-institute/reports.
---------------------------------------------------------------------------
Over the past several years, the Agency has undertaken major
initiatives to expand access to quality, affordable generic medicines.
For example, pursuant to the Generic Drug User Fee Amendments of 2012
(GDUFA I), FDA modernized the ANDA review program, and adopted metric
goals to promote timely and predictable ANDA review. As a result, in
Fiscal Year 2016, combined ANDA approvals and tentative approvals
reached record highs. Pursuant to the proposed GDUFA II,\2\ FDA would
further enhance the ANDA review program by clarifying regulatory
expectations early in product development, helping applicants develop
more complete submissions, and giving applicants more opportunities to
address deficiencies within a review cycle, all with the goal of
reducing the number of review cycles necessary to obtain ANDA approval.
---------------------------------------------------------------------------
\2\ GDUFA Reauthorization Performance Goals and Program
Enhancements Fiscal Years 2018-2022 (October 2016), available at
https://www.fda.gov/downloads/forindustry/userfees/genericdruguserfees/ucm525234.pdf.
---------------------------------------------------------------------------
The development and approval of an innovator drug, and the
subsequent approval and marketing of a generic version, together make
up the life cycle of that drug product as contemplated by the Hatch-
Waxman Amendments.
At the front end of the life cycle, innovation in drug products--
including improvements to approved innovator drug products--provides
life-changing and oftentimes life-saving therapeutic benefits to
patients. In enacting the Hatch-Waxman Amendments, Congress recognized
the importance of providing incentives to develop new products, and
[[Page 28495]]
new conditions of use for approved products. To further incentivize
innovation, Congress subsequently established additional incentives in
the form of exclusivity periods for drug products studied in pediatric
populations, rare diseases, and new antibiotic treatments. Congress
also provided a period of 180-day exclusivity for certain first generic
applications as an incentive for generic manufacturers to challenge
patents on innovator drugs that might otherwise prevent approval or
delay generic entry into the market. These exclusivities, which are
generally designed to reward sponsors with finite periods of limited or
no generic or follow-on competition, were intended to expand the
availability of safe and effective medicines for which insufficient or
no treatment previously existed or to encourage generic drug
development that might not have been profitable otherwise.
In some cases, however, the legal framework surrounding these
exclusivities may have been applied to delay generic competition to an
extent that may not have been intended by the Hatch-Waxman Amendments,
and in ways that may not serve the public health. Relatedly, certain
elements of the approval process for both innovator and generic drugs
have been used in ways that may (depending on the circumstances)
inappropriately hinder generic competition. For example, innovators in
some cases have made late changes in patent use codes that create new
obstacles to previously acceptable labeling carve-outs. The entry of
generic products to the marketplace is also affected by factors
external to regulation under the FD&C Act--e.g., the outcome of private
party patent litigation, and commercial decisions not to market
approved innovator or generic products. In other cases, restrictions on
the distribution of innovator drug products, whether voluntarily
adopted by the innovator or imposed as a requirement of FDA regulation,
have prevented developers from accessing the product samples needed for
testing to support ANDAs or other follow-on applications.
FDA will hold a public meeting on July 18, 2017, 9 a.m. to 5 p.m.,
to provide an opportunity for all interested stakeholders to submit
comments concerning the appropriate balance between encouraging
innovation in drug development and accelerating the availability to the
public of lower cost alternatives to innovator drugs.
The format of the meeting involves presentations from the public
only. The Agency will not be inviting specific presenters; rather, with
this document, FDA is soliciting presentations from interested
stakeholders. FDA also invites interested persons to submit written
comments to the docket on the topics described in section II.
II. Topics for This Public Meeting
FDA is soliciting input from the public concerning how best to
preserve the balance Congress intended to strike in the Hatch-Waxman
Amendments between encouraging innovation in drug development and
accelerating the availability to the public of lower cost alternatives
to innovator drugs. Preserving this balance is critical to the public
health, and innovators, generic drug manufacturers, and FDA (among
others) all have a role to play in maintaining it. This public meeting
is part of an effort to create a broader understanding of the interplay
between the existing legal and regulatory framework, available
incentives and marketplace practices, and consumer access to generic
drugs.
The Agency welcomes any relevant information that stakeholders wish
to share. We are particularly interested in stakeholder input on the
following questions:
1. How has the balance struck in the Hatch-Waxman Amendments been
affected by practices and trends related to the following:
a. Exclusivity periods,
b. Patents (including patent listing procedures),
c. Innovator drug product labeling,
d. Post-approval changes to innovator drug products, e.g.,
reformulations, and
e. Other regulatory processes, including the citizen petition
process?
2. The drugs described in more than half of all FDA-approved ANDAs
are never marketed, marketed only after a substantial delay after
approval, or marketed only intermittently. Such failures to market
contribute to drug shortages, and hinder consumer access to approved
products. What marketplace dynamics dis-incentivize the marketing of
approved generic products? What should FDA do, within its statutory
authority, to help more approved generics reach consumers?
3. For approximately 10 percent of all innovator drugs, patent and
exclusivity protections have expired, but FDA has not received an ANDA.
Are there market niches where the Hatch-Waxman Amendments incentives to
develop an ANDA are insufficient? Similarly, are there niches where the
incentives are insufficient to seek new drug approval of a marketed
unapproved drug product that in turn could serve as a Reference Listed
Drug? What should FDA do, consistent with its legal authority, to
encourage submission development in any such market niches?
4. The statutory requirement that Risk Evaluation and Mitigation
Strategies (REMS) that include elements to assure safe use (ETASU) be
implemented through a ``single shared system'' relies on brand and
generic companies agreeing on such a system before generic drugs may
come to market. In some cases, challenges in reaching such an agreement
between the parties may cause delays to generic competition. How should
FDA apply its statutory authority to waive this requirement to
implement a ``single shared system,'' or develop other administrative
tools, to avoid these delays?
5. Restrictions on distribution, either required by innovators or
as part of a REMS ETASU, can prevent generic companies from obtaining
drug products for bioequivalence and other testing to support ANDA
submissions. FDA published a draft guidance for industry, entitled
``How to Obtain a Letter from the Food and Drug Administration Stating
That Bioequivalence Study Protocols Contain Safety Protections
Comparable to Applicable Risk and Evaluation Mitigation Studies for
Reference Listed Drugs,'' in December 2014. Despite this draft
guidance, generic companies have reported continuing difficulties
obtaining sufficient samples of drug products for testing. What
additional actions should FDA take, within its legal authority, to
promote access to these drug products for generic companies seeking to
conduct studies required to support ANDA submissions?
6. What other elements of drug product development, regulation, and
marketing have the potential to disrupt the Hatch-Waxman Amendments'
balance between innovation and generic availability, and how should the
Agency and other stakeholders address them?
Registration and Requests for Oral Presentations: Send registration
information (including name, title, firm name, address, telephone,
email address, and fax number), and written material and requests to
make oral presentations, to the contact person by July 3, 2017.
If you need special accommodations due to a disability, please
contact Philip Bonforte (see FOR FURTHER INFORMATION CONTACT) at least
7 days in advance.
Transcripts: Please be advised that as soon as a transcript is
available, it will be accessible at https://www.regulations.gov. It may
be viewed at the Dockets Management Staff (see ADDRESSES).
[[Page 28496]]
Dated: June 14, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning, Legislation, and Analysis.
[FR Doc. 2017-12641 Filed 6-21-17; 8:45 am]
BILLING CODE 4164-01-P